Conference item
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
- Abstract:
- To estimate the degree to which cardiovascular risk reductions demonstrated with empagliflozin administration in the EMPA-REG OUTCOME trial might be explained by changes observed in conventional cardiovascular factors during the study.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 101.9KB, Terms of use)
-
- Publisher copy:
- 10.1111/dme.18_13304
Authors
- Publisher:
- Wiley
- Host title:
- Diabetes UK Professional Conference 2017
- Journal:
- Diabetes UK Professional Conference 2017 More from this journal
- Publication date:
- 2017-03-01
- Acceptance date:
- 2016-12-21
- DOI:
- ISSN:
-
0742-3071
- Pubs id:
-
pubs:721010
- UUID:
-
uuid:d4b2cfd2-3839-4400-aab3-fa8f22152a50
- Local pid:
-
pubs:721010
- Source identifiers:
-
721010
- Deposit date:
-
2017-09-21
- ARK identifier:
Terms of use
- Copyright holder:
- Coleman et al
- Copyright date:
- 2017
- Notes:
- © 2017 The Authors, presented at the Diabetes UK Professional Conference © 2017 Diabetes UK
If you are the owner of this record, you can report an update to it here: Report update to this record